Drug intelligence / Profile preview

KH309

Development stage: Unknown
Lead developer: Chengdu Kanghong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KH309 is a novel small molecule drug candidate developed by Chengdu Kanghong Biotech for the treatment of Generalized Anxiety Disorder (GAD). It is classified as a Class 1 innovative chemical drug in China. KH309 acts as an agonist at the 5-hydroxytryptamine receptor 1A (5-HT1A), a mechanism intended to provide anxiolytic effects by modulating serotonergic neurotransmission. This approach aims to offer a therapeutic alternative to benzodiazepines with a reduced risk of sedation, cognitive impairment, and physical dependence. The drug is currently undergoing clinical evaluation to establish its safety and efficacy profile in patients with anxiety disorders.

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on KH309.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KH309.

Explore the full profile